Zai Lab Ltd
ZLAB37.760USD
+0.940+2.55%
Horarios del mercado （ET）Cotizaciones retrasadas 15 min
4.09BCap. mercado
PérdidaP/E TTM
Más Datos de Zai Lab Ltd Compañía
Zai Lab Ltd is a holding company primarily engaged in biopharmaceuticals. The Company is committed to addressing the unmet medical needs in the fields of tumors, autoimmune diseases, infectious diseases and central nervous system diseases through product discovery, development and commercialization. The Company has a series of patented drug candidates from the discovery stage to the late clinical project. These include ZEJULA, OPTUNE, QINLOCK, NUZYRA and VYVGART, and others.
Información de la empresa
Símbolo de cotizaciónZLAB
Nombre de la empresaZai Lab Ltd
Fecha de salida a bolsaSep 28, 2020
Director ejecutivoDr. Du (Samantha) Ying, Ph.D.
Número de empleados1869
Tipo de seguridadDepository Receipt
Fin del año fiscalSep 28
DirecciónBuilding B, 899 Halei Road, Pudong
CiudadSHANGHAI
Bolsa de valoresNASDAQ Global Market Consolidated
PaísChina
Código postal201203
Teléfono862161632588
Sitio Webhttps://www.zailaboratory.com/
Símbolo de cotizaciónZLAB
Fecha de salida a bolsaSep 28, 2020
Director ejecutivoDr. Du (Samantha) Ying, Ph.D.
Ejecutivos de la empresa
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. John David Diekman, Ph.D.
Dr. John David Diekman, Ph.D.
Lead Independent Director
Lead Independent Director
99.77K
+12.18%
Mr. Joshua L. Smiley
Mr. Joshua L. Smiley
President, Chief Operating Officer
President, Chief Operating Officer
67.34K
+55.78%
Mr. William David (Bill) Lis
Mr. William David (Bill) Lis
Independent Director
Independent Director
35.11K
-7.83%
Dr. Yajing Chen, Ph.D.
Dr. Yajing Chen, Ph.D.
Chief Financial Officer
Chief Financial Officer
21.00K
-22.34%
Dr. Du (Samantha) Ying, Ph.D.
Dr. Du (Samantha) Ying, Ph.D.
Chairman of the Board, Chief Executive Officer, Co-Founder
Chairman of the Board, Chief Executive Officer, Co-Founder
--
--
Mr. Leon Oliver (Lonnie) Moulder, Jr.
Mr. Leon Oliver (Lonnie) Moulder, Jr.
Independent Director
Independent Director
--
--
Mr. Michel Pericles Vounatsos
Mr. Michel Pericles Vounatsos
Independent Director
Independent Director
--
--
Dr. Richard B. Gaynor, M.D.
Dr. Richard B. Gaynor, M.D.
Independent Director
Independent Director
--
--
Ms. Leung (Nisa Bernice) Wing-Yu
Ms. Leung (Nisa Bernice) Wing-Yu
Independent Director
Independent Director
--
--
Mr. Peter Karl Wirth, J.D.
Mr. Peter Karl Wirth, J.D.
Independent Director
Independent Director
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. John David Diekman, Ph.D.
Dr. John David Diekman, Ph.D.
Lead Independent Director
Lead Independent Director
99.77K
+12.18%
Mr. Joshua L. Smiley
Mr. Joshua L. Smiley
President, Chief Operating Officer
President, Chief Operating Officer
67.34K
+55.78%
Mr. William David (Bill) Lis
Mr. William David (Bill) Lis
Independent Director
Independent Director
35.11K
-7.83%
Dr. Yajing Chen, Ph.D.
Dr. Yajing Chen, Ph.D.
Chief Financial Officer
Chief Financial Officer
21.00K
-22.34%
Dr. Du (Samantha) Ying, Ph.D.
Dr. Du (Samantha) Ying, Ph.D.
Chairman of the Board, Chief Executive Officer, Co-Founder
Chairman of the Board, Chief Executive Officer, Co-Founder
--
--
Mr. Leon Oliver (Lonnie) Moulder, Jr.
Mr. Leon Oliver (Lonnie) Moulder, Jr.
Independent Director
Independent Director
--
--
Desglose de ingresos
Divisa: USDActualizado: dom., 6 de jul
Divisa: USDActualizado: dom., 6 de jul
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
Por negocioUSD
Nombre
Ganancia
Proporción
ZEJULA
49.53M
46.88%
VYVGART
18.11M
17.14%
NUZYRA
15.12M
14.31%
Optune
11.36M
10.76%
QINLOCK
8.51M
8.05%
Other
3.03M
2.86%
Sin datos
Por negocio
Por región
Por negocioUSD
Nombre
Ganancia
Proporción
ZEJULA
49.53M
46.88%
VYVGART
18.11M
17.14%
NUZYRA
15.12M
14.31%
Optune
11.36M
10.76%
QINLOCK
8.51M
8.05%
Other
3.03M
2.86%
Estadísticas de accionistas
Actualizado: dom., 3 de ago
Actualizado: dom., 3 de ago
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
Capital World Investors
5.41%
Fidelity Management & Research Company LLC
4.21%
Janus Henderson Investors
3.43%
Wellington Management Company, LLP
3.28%
ClearBridge Investments, LLC
2.95%
Other
80.71%
Accionistas
Accionistas
Proporción
Capital World Investors
5.41%
Fidelity Management & Research Company LLC
4.21%
Janus Henderson Investors
3.43%
Wellington Management Company, LLP
3.28%
ClearBridge Investments, LLC
2.95%
Other
80.71%
Tipos de accionistas
Accionistas
Proporción
Investment Advisor
20.70%
Investment Advisor/Hedge Fund
19.15%
Hedge Fund
5.67%
Research Firm
2.88%
Individual Investor
1.42%
Venture Capital
1.39%
Pension Fund
0.67%
Private Equity
0.32%
Sovereign Wealth Fund
0.18%
Other
47.63%
Participación institucional
Actualizado: mar., 1 de jul
Actualizado: mar., 1 de jul
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q2
393
64.25M
57.85%
-6.53M
2025Q1
453
59.51M
53.68%
-14.18M
2024Q4
446
60.80M
55.47%
-4.29M
2024Q3
439
51.45M
51.99%
-10.14M
2024Q2
454
47.04M
47.66%
-14.67M
2024Q1
465
46.22M
46.47%
-13.77M
2023Q4
497
46.31M
46.92%
-16.57M
2023Q3
537
44.27M
45.68%
-20.42M
2023Q2
568
47.21M
48.74%
-23.76M
2023Q1
572
60.29M
61.61%
-11.82M
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
Capital World Investors
6.01M
5.41%
-425.00K
-6.61%
Mar 31, 2025
Fidelity Management & Research Company LLC
4.68M
4.21%
+945.91K
+25.33%
Mar 31, 2025
Janus Henderson Investors
3.81M
3.43%
-2.75M
-41.94%
Mar 31, 2025
Wellington Management Company, LLP
3.65M
3.28%
-3.01M
-45.22%
Mar 31, 2025
ClearBridge Investments, LLC
3.28M
2.95%
+1.42M
+76.05%
Mar 31, 2025
RTW Investments L.P.
3.14M
2.82%
+627.56K
+25.01%
Mar 31, 2025
Principal Global Investors (Equity)
2.88M
2.6%
+1.12M
+63.64%
Mar 31, 2025
Morgan Stanley & Co. LLC
2.45M
2.2%
-532.32K
-17.86%
Mar 31, 2025
T. Rowe Price Associates, Inc.
2.27M
2.04%
-85.81K
-3.65%
Mar 31, 2025
Baron Capital Management, Inc.
1.83M
1.65%
-79.59K
-4.17%
Mar 31, 2025
Ver más
ETFs relacionados
Actualizado: sáb., 2 de ago
Actualizado: sáb., 2 de ago
Nombre
Proporción
Tema Oncology ETF
3.06%
ALPS Medical Breakthroughs ETF
2.67%
Virtus LifeSci Biotech Products ETF
1.57%
Invesco Golden Dragon China ETF
1.14%
Innovator IBD 50 Fund ETF
0.94%
National Security Emerging Markets Index ETF
0.43%
iShares Biotechnology ETF
0.25%
ProShares Ultra Nasdaq Biotechnology
0.23%
Invesco Nasdaq Biotechnology ETF
0.23%
Capital Group New Geography Equity ETF
0.21%
Ver más
Tema Oncology ETF
Proporción3.06%
ALPS Medical Breakthroughs ETF
Proporción2.67%
Virtus LifeSci Biotech Products ETF
Proporción1.57%
Invesco Golden Dragon China ETF
Proporción1.14%
Innovator IBD 50 Fund ETF
Proporción0.94%
National Security Emerging Markets Index ETF
Proporción0.43%
iShares Biotechnology ETF
Proporción0.25%
ProShares Ultra Nasdaq Biotechnology
Proporción0.23%
Invesco Nasdaq Biotechnology ETF
Proporción0.23%
Capital Group New Geography Equity ETF
Proporción0.21%
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Tipo
Relación
Sin datos
Fecha
Tipo
Relación
Sin datos
